In a nutshell This review outlines the treatment options for Hodgkin lymphoma that has relapsed or that did not respond to treatment. Some background Standard treatment for Hodgkin lymphoma is a combination of chemotherapy and radiation. More than 80% of patients achieve long-term cure with these treatments. Some patients do not respond to...
Read More
In a nutshell This study examined the use of nivolumab (Opdivo) in patients with heavily pretreated Hodgkin lymphoma. The authors concluded that nivolumab was effective and safe in these patients. Some background PD-1 is a protein that slows the immune response. Many cancer cells use the PD-1 pathway to block the immune system from attacking...
Read More
In a nutshell This trial examined the longer-term effectiveness of brentuximab vedotin (Adcetris) after stem cell transplant in patients with relapsed or refractory (did not respond to treatment) Hodgkin lymphoma. The authors concluded that patients who respond to brentuximab vedotin can achieve long-term disease control. Some background...
Read MoreIn a nutshell This study examined the safety and effectiveness of the chemotherapy combination IGEV. This study concluded that this combination benefitted patients with Hodgkin lymphoma who had relapsed or who had not responded to other treatment. Some background Recent treatments for Hodgkin lymphoma have led to very high cure rates. Some...
Read More
